ERBB2 and breast cancer: Since HER2+ BC is characterized by dense immunological cell infiltration and reduced immune exhaustion [4], immune checkpoint inhibitors combined with standard anti-HER2 drugs have demonstrated success in the treatment of HER2+ BC [5].